Literature DB >> 25190764

Management of melanoma.

Pippa Corrie1, Mirela Hategan2, Kate Fife2, Christine Parkinson2.   

Abstract

BACKGROUND: Melanoma is a potentially curable cancer, but around 20% of patients will develop disease which is beyond surgical clearance. Rising incidence alongside breakthroughs in understanding the molecular biology of this disease identifying systemic therapies offering survival gains now demand a more proactive, integrated approach to melanoma management. SOURCES OF DATA: PubMed references relating to aspects of melanoma research and treatment. AREAS OF AGREEMENT: Rapidly rising incidence throughout the world. Effective surgery as well as new molecular targeted systemic biological agents and immunotherapies necessitating early diagnosis and multidisciplinary therapeutic interventions. AREAS OF CONTROVERSY: Role of screening and prevention. Benefit of interventions for locoregional melanoma, including role of sentinel lymph node biopsy. Integration and sequencing of treatments for unresectable melanoma. GROWING POINTS: Molecular determinants of melanoma influencing disease outcome and treatment decisions. AREAS TIMELY FOR DEVELOPING RESEARCH: Education and training of patient and healthcare professionals. Role of screening, surveillance and follow-up strategies. Biology of melanoma guiding treatment decisions.
© The Author 2014. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  advanced melanoma; diagnosis; epidemiology; melanoma; metastatic melanoma; prevention; primary melanoma; screening; treatment

Mesh:

Substances:

Year:  2014        PMID: 25190764     DOI: 10.1093/bmb/ldu019

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  26 in total

1.  [miR-122-5p inhibits the proliferation of melanoma cells by targeting NOP14].

Authors:  Jingrong Li; Rui Zhao; Ruihua Fang; Jianqin Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Authors:  Bradley Garman; Ioannis N Anastopoulos; Clemens Krepler; Patricia Brafford; Katrin Sproesser; Yuchao Jiang; Bradley Wubbenhorst; Ravi Amaravadi; Joseph Bennett; Marilda Beqiri; David Elder; Keith T Flaherty; Dennie T Frederick; Tara C Gangadhar; Michael Guarino; David Hoon; Giorgos Karakousis; Qin Liu; Nandita Mitra; Nicholas J Petrelli; Lynn Schuchter; Batool Shannan; Carol L Shields; Jennifer Wargo; Brandon Wenz; Melissa A Wilson; Min Xiao; Wei Xu; Xaiowei Xu; Xiangfan Yin; Nancy R Zhang; Michael A Davies; Meenhard Herlyn; Katherine L Nathanson
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

Review 3.  Immunotherapy and targeted therapy-the new roadmap in cancer treatment.

Authors:  Kamran Shahid; Mustafa Khalife; Raetasha Dabney; Alexandria T Phan
Journal:  Ann Transl Med       Date:  2019-10

4.  MicroRNA-373 promotes cell migration via targeting salt-inducible kinase 1 expression in melanoma.

Authors:  Xinping Bai; Ming Yang; Yi Xu
Journal:  Exp Ther Med       Date:  2018-09-21       Impact factor: 2.447

5.  Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.

Authors:  R R Maniyar; S Chakraborty; T Jarboe; R Suriano; M Wallack; J Geliebter; R K Tiwari
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

Authors:  Samanta Sharma; Tian Zhang; Wojciech Michowski; Vito W Rebecca; Min Xiao; Roberta Ferretti; Jan M Suski; Roderick T Bronson; Joao A Paulo; Dennie Frederick; Anne Fassl; Genevieve M Boland; Yan Geng; Jacqueline A Lees; Rene H Medema; Meenhard Herlyn; Steven P Gygi; Piotr Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-19       Impact factor: 11.205

7.  Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma.

Authors:  M J Rutherford; L Ironmonger; N Ormiston-Smith; G A Abel; D C Greenberg; G Lyratzopoulos; P C Lambert
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

8.  Clinical Characteristics of Malignant Melanoma in Southwest China: A Single-Center Series of 82 Consecutive Cases and a Meta-Analysis of 958 Reported Cases.

Authors:  Jia Yu; Xue Luo; Hui Huang; Zhifang Zhai; Zhu Shen; Hui Lin
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  A new metabolic signature contributes to disease progression and predicts worse survival in melanoma.

Authors:  Mengdi Wan; Binyu Zhuang; Xiao Dai; Liang Zhang; Fangqing Zhao; Yan You
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

10.  CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.

Authors:  Ruchi Saxena; Yan Wang; James W Mier
Journal:  Melanoma Res       Date:  2020-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.